Phase 3 Readout
GHRS: Phase 3 Topline: A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy
July 16, 2026 · guselkumab. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- July 16, 2026
- Company
- GH Research PLC (GHRS)
- Drug
- guselkumab
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy
- Company
- GH Research PLC (GHRS)
- Drug
- guselkumab
- Indication
- Arthritis, Psoriatic
Other upcoming events for GHRS
Phase 1 StartPhase 1 Start: A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics an
Phase 2 StartPhase 2 Start: Investigating Novel Interventions for Low Back Pain in US Military Veterans: A Randomized Controlled
Phase 2 StartPhase 2 Start: Ultra-low Dose Transdermal Estradiol Therapy in Prepubertal Girls With Turner Syndrome and Primary O
Phase 2 StartPhase 2 Start: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial to Evaluat
Phase 1 StartPhase 1 Start: Pilot Radioembolisation Clinical Trial Assessing Safety and Efficacy in Recurrent Glioma (PRECISE)